AU2018227737B2 - Polypeptide, polypeptide fragment, derivative thereof, and applications thereof - Google Patents

Polypeptide, polypeptide fragment, derivative thereof, and applications thereof Download PDF

Info

Publication number
AU2018227737B2
AU2018227737B2 AU2018227737A AU2018227737A AU2018227737B2 AU 2018227737 B2 AU2018227737 B2 AU 2018227737B2 AU 2018227737 A AU2018227737 A AU 2018227737A AU 2018227737 A AU2018227737 A AU 2018227737A AU 2018227737 B2 AU2018227737 B2 AU 2018227737B2
Authority
AU
Australia
Prior art keywords
seq
polypeptide
pct
derivative
english translation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018227737A
Other languages
English (en)
Other versions
AU2018227737A2 (en
AU2018227737A1 (en
Inventor
Ling Chen
Rui Chen
Xiaohong Chen
Yi Ding
Xiaomei Li
De Wei
Ling Xiao
Wen Yu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chengdu Huitai Biomedicine Co Ltd
Original Assignee
Chengdu Huitai Biomedicine Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN201710115604.4A external-priority patent/CN106860855B/zh
Priority claimed from CN201710677602.4A external-priority patent/CN109384830B/zh
Application filed by Chengdu Huitai Biomedicine Co Ltd filed Critical Chengdu Huitai Biomedicine Co Ltd
Publication of AU2018227737A1 publication Critical patent/AU2018227737A1/en
Publication of AU2018227737A2 publication Critical patent/AU2018227737A2/en
Application granted granted Critical
Publication of AU2018227737B2 publication Critical patent/AU2018227737B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
AU2018227737A 2017-03-01 2018-02-28 Polypeptide, polypeptide fragment, derivative thereof, and applications thereof Active AU2018227737B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201710115604.4 2017-03-01
CN201710115604.4A CN106860855B (zh) 2017-03-01 2017-03-01 多肽及多肽衍生物在预防和治疗纤维化疾病中的应用
CN201710677602.4A CN109384830B (zh) 2017-08-09 2017-08-09 多肽、多肽片段及其衍生物在防治纤维化疾病中的应用
CN201710677602.4 2017-08-09
PCT/CN2018/077492 WO2018157807A1 (zh) 2017-03-01 2018-02-28 多肽、多肽片段及其衍生物与应用

Publications (3)

Publication Number Publication Date
AU2018227737A1 AU2018227737A1 (en) 2019-10-17
AU2018227737A2 AU2018227737A2 (en) 2020-01-30
AU2018227737B2 true AU2018227737B2 (en) 2021-04-01

Family

ID=63369746

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018227737A Active AU2018227737B2 (en) 2017-03-01 2018-02-28 Polypeptide, polypeptide fragment, derivative thereof, and applications thereof

Country Status (9)

Country Link
US (2) US12011475B2 (enExample)
EP (1) EP3590527A4 (enExample)
JP (1) JP6965362B2 (enExample)
KR (1) KR102368159B1 (enExample)
AU (1) AU2018227737B2 (enExample)
CA (1) CA3054839C (enExample)
IL (1) IL268971B2 (enExample)
SG (1) SG11201907914QA (enExample)
WO (1) WO2018157807A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7302120B2 (ja) * 2015-10-27 2023-07-04 タイペイ メディカル ユニバーシティ 線維症疾患の治療及び／又は予防用インドリン誘導体
CN112386678B (zh) * 2019-08-13 2023-07-07 成都惠泰生物医药有限公司 多肽或其衍生物的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009043525A2 (en) * 2007-09-11 2009-04-09 Mondobiotech Laboratories Ag Use of the combination of gluten exorphin c and cd36 as a therapeutic agent

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9509957D0 (en) * 1995-05-17 1995-07-12 Khalil Nasreen Post-translational activation of tgf-›1 involving the tsp-1 receptor cd36
US7601691B2 (en) 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
DK1105409T3 (da) 1999-05-17 2006-07-03 Conjuchem Inc Beskyttelse af endogene terapeutiske peptider fra peptidaseaktivitet ved konjugering med blodkomponenter
AU2002347182A1 (en) 2001-12-18 2003-06-30 Mondobiotech Licensing Out Ag Pharmaceutical composition of interferon gamma or pirfenidone with molecular diagnostics for the improved treatment of interstitial lung diseases
WO2009039966A2 (en) 2007-09-11 2009-04-02 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
KR20130087585A (ko) * 2010-11-24 2013-08-06 에프. 호프만-라 로슈 아게 저도 염증을 검출하는 방법
LT2714735T (lt) 2011-06-03 2021-12-10 Xoma Technology Ltd. Tgf beta specifiniai antikūnai
US10035823B2 (en) 2014-09-29 2018-07-31 The Regents Of The University Of California Compositions for expanding regulatory T cells (TREG), and treating autoimmune and inflammatory diseases and conditions
CN104313028A (zh) 2014-09-30 2015-01-28 北京生科东方科技有限公司 抗类风湿关节炎的小肽基因及其生产方法
CN105061600A (zh) 2015-09-05 2015-11-18 苏州普罗达生物科技有限公司 类风湿因子IgA抑制多肽及其应用
CN106860855B (zh) * 2017-03-01 2021-06-11 成都惠泰生物医药有限公司 多肽及多肽衍生物在预防和治疗纤维化疾病中的应用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009043525A2 (en) * 2007-09-11 2009-04-09 Mondobiotech Laboratories Ag Use of the combination of gluten exorphin c and cd36 as a therapeutic agent

Also Published As

Publication number Publication date
CA3054839A1 (en) 2018-09-07
US20220072082A1 (en) 2022-03-10
WO2018157807A1 (zh) 2018-09-07
IL268971B1 (en) 2023-09-01
EP3590527A4 (en) 2021-01-06
JP6965362B2 (ja) 2021-11-10
CA3054839C (en) 2023-08-29
KR102368159B1 (ko) 2022-03-03
US12011475B2 (en) 2024-06-18
AU2018227737A2 (en) 2020-01-30
AU2018227737A1 (en) 2019-10-17
IL268971A (en) 2019-10-31
KR20190125373A (ko) 2019-11-06
US20240390450A1 (en) 2024-11-28
SG11201907914QA (en) 2019-09-27
IL268971B2 (en) 2024-01-01
EP3590527A1 (en) 2020-01-08
JP2020509061A (ja) 2020-03-26

Similar Documents

Publication Publication Date Title
CN106860855B (zh) 多肽及多肽衍生物在预防和治疗纤维化疾病中的应用
CN109384830B (zh) 多肽、多肽片段及其衍生物在防治纤维化疾病中的应用
US20240390450A1 (en) Polypeptide, polypeptide fragment, derivative thereof, and applications thereof
JP7597398B2 (ja) 組換え神経成長因子のための組成物及び方法
US9938320B2 (en) Peptides for promoting angiogenesis and use thereof
Qi et al. Tissue inhibitor of metalloproteinases-3 peptides inhibit angiogenesis and choroidal neovascularization in mice
KR102519869B1 (ko) 골형성단백질의 치료적 용도
US20220280594A1 (en) Application of polypeptide or derivative thereof
CN111423502A (zh) 多肽、其衍生物及其在制备抗肺纤维化的药物中的应用
US9249185B2 (en) Peptides for promoting angiogenesis and an use thereof
HK40015944A (en) Polypeptide, polypeptide fragment, derivative thereof, and applications thereof
KR102629203B1 (ko) 별아교세포 선택적 펩타이드가 결합된 나노입자 및 이의 용도
US20110092427A1 (en) Polypeptide and pharmaceutical composition containing the polypeptide
US20250263456A1 (en) Use of fgf5 transcript variant-2 and protein thereof in preventing, inhibiting, or treating liver fibrosis
Liu et al. Bioactive nanofiber hydrogel acts on VEGF and VEGF receptor to unleash inhibition effects on corneal neovascularization
CN116253776A (zh) 靶向抑制trib3的多肽及其用途
WO2025096630A2 (en) Collagen peptide-based medicament compositions and uses thereof
Qi et al. Tissue Inhibitor of Metalloproteinases-3 Peptides Inhibit Angiogenesis and Choroidal
WO2021052277A1 (zh) 重组人神经调节蛋白衍生物及其用途
HK1147502A (en) Polypeptide and pharmaceutical composition containing the polypeptide
HK1245149A1 (en) Wt1 immunotherapy for intraocular angiogenic disease

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENTS FILED 25 SEP 2019 AND 09 JAN 2020

FGA Letters patent sealed or granted (standard patent)